Biomolecular Condensates in Disease: Decoding the Material State and Engineering Precision Modulators

TL;DR

This paper explores how disruptions in biomolecular condensates contribute to disease and proposes new strategies to precisely modulate these structures for therapeutic purposes.

Contribution

The paper introduces a novel approach to targeting condensate dysfunction by reverse-engineering biophysical codes and developing programmable molecular tools.

Findings

Dysregulation of biomolecular condensates is linked to a wide range of diseases termed 'Condensatopathies'.

Current drug approaches are insufficient for addressing condensate-related disorders due to their complex nature.

Synthetic peptides and state-specific degraders offer promising tools for modulating pathological condensates.

Abstract

The recognition of liquid–liquid phase separation (LLPS) as a widespread organizing principle has revolutionized our view of cellular biochemistry. By forming biomolecular condensates, cells spatially orchestrate reactions without membranes. However, the dysregulation of this precise physical organization is emerging as a driver of diverse pathologies, collectively termed “Condensatopathies.” Unlike traditional proteinopathies defined by static aggregates, these disorders span a dynamic spectrum of material state dysfunctions, from the failure to assemble essential compartments to the formation of aberrant, toxic phases. While research has largely focused on neurodegeneration and cancer, the impact of condensate dysfunction likely extends across broad physiological landscapes. A central unresolved challenge lies in deciphering the “molecular grammar” that governs the transition from functional fluids to pathological solids and, critically, visualizing these transitions in situ. This “material science” perspective presents a profound conundrum for drug discovery: how to target the collective physical state of a protein ensemble rather than a fixed active site. This review navigates the evolving therapeutic horizon, examining the limitations of current pharmacological approaches in addressing the complex “condensatome.” Moving beyond inhibition, we propose that the future of intervention lies in “reverse-engineering” the biophysical codes of phase separation. We discuss how deciphering these principles enables the creation of programmable molecular tools—such as synthetic peptides and state-specific degraders—designed to precisely modulate or dismantle pathological condensates, paving the way for a new era of precision medicine governed by soft matter physics.

Figures